Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 9/20 | 1.00 |
| ▸ | SUV39H1 | O43463 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.72 |
| ▸ | EP300 | Q09472 | 2/20 | 0.72 |
| ▸ | NSD2 | O96028 | 1/20 | 0.72 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.72 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.72 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779939 | 1.00 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| SCHEMBL29623118 | 1.00 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| SCHEMBL29390533 | 1.00 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| SCHEMBL22963777 | 0.91 | EHMT2 (0.83) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| SCHEMBL18294715 | 0.87 | EHMT2 (0.75) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| SCHEMBL15856811 | 0.85 | EHMT2 (0.72) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| Chaetocin SCHEMBL20796284 | 0.84 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| Chaetocin SCHEMBL22065398 | 0.84 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| Chaetocin SCHEMBL19382420 | 0.84 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 | |
| Chaetocin SCHEMBL13662582 | 0.84 | EHMT2 (1.00) | EHMT2SUV39H1HIF1AEP300NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918735-B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190255187-A1 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-22 | — | — | US | disclosed |
| US-10220099-B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255187-A1 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT | IDO1, NPY1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EHMT2 1551/4885SUV39H1 2673/4885HIF1A 3839/4885 |
| US-10918735-B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | IDO1, IDO2, INMT | EHMT2 2850/4885SUV39H1 3470/4885HIF1A 2056/4885 |
| US-10220099-B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | IDO1, NPY1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EHMT2 1562/4885SUV39H1 2722/4885HIF1A 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.